WallStreetZenWallStreetZen

NASDAQ: BLCM
Bellicum Pharmaceuticals Inc Stock

$0.32+0.00 (+0%)
Updated Mar 21, 2023
BLCM Price
$0.32
Fair Value Price
$1.25
Market Cap
$2.73M
52 Week Low
$0.27
52 Week High
$2.20
P/E
-1.32x
P/B
0.36x
P/S
24.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.50M
Earnings
-$16.25M
Gross Margin
100%
Operating Margin
-1,083%
Profit Margin
-1,083%
Debt to Equity
0.77
Operating Cash Flow
-$25M
Beta
1.03
Next Earnings
Mar 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BLCM Overview

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLCM ($0.32) is undervalued by 74.63% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BLCM ($0.32) is significantly undervalued by 74.63% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BLCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLCM due diligence checks available for Premium users.

Be the first to know about important BLCM news, forecast changes, insider trades & much more!

BLCM News

Valuation

BLCM fair value

Fair Value of BLCM stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$1.25
Undervalued by
74.39%
BLCM ($0.32) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLCM ($0.32) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BLCM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.32x
Industry
16.62x
Market
22.45x

BLCM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.36x
Industry
4.85x
BLCM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BLCM's financial health

Profit margin

Revenue
$1.0M
Net Income
-$7.2M
Profit Margin
-721.3%
BLCM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BLCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$31.3M
Liabilities
$5.7M
Debt to equity
0.77
BLCM's short-term assets ($31.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLCM's short-term assets ($31.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLCM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.9M
Investing
$0.0
Financing
$0.0
BLCM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BLCM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BLCM$2.73M0.00%-1.32x0.36x
PALI$2.79M+4.62%0.20x0.22x
FRTX$2.65M+1.26%-0.13x0.24x
NVIV$2.81M+1.87%-0.14x0.18x
HOTH$2.82M+5.34%-0.21x0.33x

Bellicum Pharmaceuticals Stock FAQ

What is Bellicum Pharmaceuticals's quote symbol?

NASDAQ: BLCM) Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol BLCM. Bellicum Pharmaceuticals stock quotes can also be displayed as NASDAQ: BLCM.

If you're new to stock investing, here's how to buy Bellicum Pharmaceuticals stock.

What is the 52 week high and low for Bellicum Pharmaceuticals (NASDAQ: BLCM)?

(NASDAQ: BLCM) Bellicum Pharmaceuticals's 52-week high was $2.20, and its 52-week low was $0.27. It is currently -85.59% from its 52-week high and 17.41% from its 52-week low.

How much is Bellicum Pharmaceuticals stock worth today?

(NASDAQ: BLCM) Bellicum Pharmaceuticals currently has 8,613,527 outstanding shares. With Bellicum Pharmaceuticals stock trading at $0.32 per share, the total value of Bellicum Pharmaceuticals stock (market capitalization) is $2.73M.

Bellicum Pharmaceuticals stock was originally listed at a price of $238.80 in Dec 18, 2014. If you had invested in Bellicum Pharmaceuticals stock at $238.80, your return over the last 8 years would have been -99.87%, for an annualized return of -56.31% (not including any dividends or dividend reinvestments).

How much is Bellicum Pharmaceuticals's stock price per share?

(NASDAQ: BLCM) Bellicum Pharmaceuticals stock price per share is $0.32 today (as of Mar 21, 2023).

What is Bellicum Pharmaceuticals's Market Cap?

(NASDAQ: BLCM) Bellicum Pharmaceuticals's market cap is $2.73M, as of Mar 22, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bellicum Pharmaceuticals's market cap is calculated by multiplying BLCM's current stock price of $0.32 by BLCM's total outstanding shares of 8,613,527.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.